Peter Guzzo, Ph.D., CEO and Co-founder

Dr. Peter Guzzo brings to ConSynance over 20 years of leadership experience in interdisciplinary drug discovery. He previously led large teams of scientists as part of an international R&D effort at AMRI. He was responsible for the management and strategic planning of an R&D portfolio which included CNS (psychiatric diseases), metabolic disease and anti-tumor (traditional and ligand-drug conjugates) projects that produced four clinical compounds, and multiple candidate compounds. Dr. Guzzo is familiar with US and international patent law and has been involved in the technology transfer/licensing of multiple projects. He has published 43 papers in peer-reviewed journals, multiple conference invitations and is the inventor of 43 US patents/applications. Pete holds a Ph.D. in Organic Chemistry from University of Notre Dame and completed postdoctoral training at Rensselaer Polytechnic Institute.

Shuang Liu, Ph.D., President and Co-founder

Dr. Liu is an experienced drug discovery leader with a proven record of success. For 18 years, she managed a number of drug discovery projects for both clients and AMRI’s internal R&D efforts in central nervous system, oncology, autoimmune and metabolic diseases. She was the co-project leader of AMRI’s triple reuptake inhibitor program which was successfully licensed to BMS in 2005. She then led the Medicinal chemistry team in collaboration with BMS to deliver 4 development candidates; the furthest advanced, BMS-820836 (liafensine), completed Phase IIB. She is the co-inventor of more than 30 US patents/applications and co-author of 17 peer reviewed articles. Shuang holds a B.S. in chemistry from Beijing Normal University and Ph.D. in Organic Chemistry from University of Georgia. She completed her post-doctoral training at Emory University.